Sustained Improvement in Renal Function with Palopegteriparatide in Adults with Chronic Hypoparathyroidism: 2-Year Results from the Phase 3 PaTHway-Trial
Clicks: 5
ID: 314577
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.6
/100
5 views
2 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #46 of 120 articles by views in journal of bone and mineral research : the official journal of the american society for bone and mineral research
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
The PaTHway clinical trial demonstrated sustained efficacy, safety, and tolerability of daily palopegteriparatide in the treatment of adults with hypoparathyroidism. Palopegteriparatide treatment was also associated with improvements in eGFR over 52 weeks in a post hoc analysis, prompting further exploration of palopegteriparatide in the preservation of renal function. The current post hoc analysis evaluated the impact of palopegteriparatide treatment on renal function in adults with hypoparathyroidism through Week 104; as with prior analysis, changes in renal function were assessed using eGFR. At Week 104, 93% (76/82) of participants remained in the open-label extension. Of those, 82% had albumin-adjusted serum calcium levels in the normal range (8.3-10.6 mg/dL), 97% were independent from conventional therapy (≤ 600 mg/day of elemental calcium and no active vitamin D). Mean (SD) serum phosphate (3.5 (0.7) mg/dL) and albumin-adjusted calcium x phosphate product (30.7(5.1) mg2/dL2) levels were also within normal ranges. Palopegteriparatide treatment resulted in a mean (SD) increase in eGFR of 8.9 (11.0) mL/min/1.73m2 (P<0.0001) from baseline to Week 52, which was sustained through Week 104, where it was 77.8 (14.8) mL/min/1,73m2 with a mean (SD) change from baseline of 9.0 (10.3) mL/min/1.73 m2 (P < 0.0001). By Week 104, 45% and 34% of participants had an increase in eGFR of ≥ 5 mL/min/1.73 m2 and ≥ 10 mL/min/1.73 m2, respectively. Palopegteriparatide treatment normalized mean (SD) 24-hour urine calcium within 26 weeks and maintained levels below 250 mg/day through Week 104 (158.8 (90.5) mg/24 h). Most treatment-emergent adverse events were mild or moderate; no new safety signals or cases of treatment-related nephrolithiasis were reported. These findings demonstrate sustained renal safety of palopegteriparatide and suggest that PTH replacement therapy with palopegteriparatide preserves and may improve renal function in adults with chronic hypoparathyroidism after 104 weeks of treatment.
| Reference Key |
openalex_W7162005957
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Lars Rejnmark, Elvira O. Gosmanova, Aliya Khan, Stuart Sprague, Dolores Shoback, L Kohlmeier, Mishaela R. Rubin, Andrea Palermo, Peter Schwarz, Claudia Gagnon, Elena Tsourdi, Yasuhiro Takeuchi, Noriko Makita, Yasuo Imanishi, Neil Gittoes, Juan J. Díez, Caroline Prot‐Bertoye, Bryant Lai, Carol Zhao, Jenny Ukena, Michael Makara, Christopher T. Sibley, Aimee D Shu |
| Journal | journal of bone and mineral research : the official journal of the american society for bone and mineral research |
| Year | 2026 |
| DOI |
10.1093/jbmr/zjag085
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.